SCHEMBL30857984

SCHEMBL30857984

Cc1cc2c(=O)cc(-c3ccncc3)oc2c(C(C)N)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 1/20 0.49
▸ PIK3CA P42336 1/20 0.49
▸ PIK3CB P42338 1/20 0.49
▸ PIK3CG P48736 1/20 0.49
▸ CYP1A1 P04798 9/20 0.49
▸ CYP1B1 Q16678 9/20 0.49
▸ CYP1A2 P05177 8/20 0.49
▸ CFTR P13569 2/20 0.49
▸ POLB P06746 1/20 0.49
▸ CYP3A4 P08684 2/20 0.46
▸ CYP2C19 P33261 2/20 0.46
▸ NCOA1 Q15788 1/20 0.46
▸ NCOA3 Q9Y6Q9 1/20 0.46
▸ QPCT Q16769 1/20 0.42
▸ CSNK2A2 P19784 2/20 0.41
▸ CSNK2B P67870 2/20 0.41
▸ CSNK2A1 P68400 2/20 0.41
▸ PRKDC P78527 3/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30857996 0.80 CYP1A1 (0.53) PIK3CDPIK3CAPIK3CBPIK3CGCYP1A1
SCHEMBL27385365 0.76 PIK3CA (0.52) PIK3CDPIK3CAPIK3CBPIK3CGCYP1A1
SCHEMBL27384001 0.76 PIK3CA (0.52) PIK3CDPIK3CAPIK3CBPIK3CGCYP1A1
SCHEMBL27383027 0.76 PIK3CA (0.52) PIK3CDPIK3CAPIK3CBPIK3CGCYP1A1
SCHEMBL30857944 0.72 PIK3CA (0.46) PIK3CDPIK3CAPIK3CBPIK3CGCYP1A1
SCHEMBL30857976 0.72 PIK3CA (0.46) PIK3CDPIK3CAPIK3CBPIK3CGCYP1A1
Trifluoroacetic Acid SCHEMBL30857932 0.72 PIK3CA (0.48) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL30857904 0.72 PIK3CA (0.46) PIK3CDPIK3CAPIK3CBPIK3CGCYP1A1
SCHEMBL909859 0.72 PIK3CD (0.67) PIK3CDPIK3CAPIK3CBPIK3CGCYP1A1
SCHEMBL910336 0.72 PIK3CD (0.67) PIK3CDPIK3CAPIK3CBPIK3CGCYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4602031-A1 METHODS FOR TREATING CANCER Genesis Therapeutics, Inc. (US) 2025-08-20 — — EP disclosed
WO-2024081904-A1 METHODS FOR TREATING CANCER GENESIS THERAPEUTICS, INC. (US) 2024-04-18 — — WO disclosed
Send feedback